The Clinical Efficacy of Isoniazid Combined with Moxifloxacin in Drug-Re-sistant Pulmonary Tuberculosis Patients and Its Impact on Inflammatory Factors
Objective This study aims to evaluate the clinical efficacy of isoniazid combined with moxifloxacin in the treatment of drug-resistant pulmonary tuberculosis patients and its effects on inflammatory factors.Methods A retrospective analysis was conducted on the medical records of 120 drug-resistant pulmonary tuberculosis patients treated at Cangzhou Third Hospital from January 2022 to January 2024.The patients were divided into two groups:a control group(58 cases)and an observation group(62 cases).The control group was treated with isoniazid,while the observation group received a combina-tion therapy of isoniazid and moxifloxacin.Clinical efficacy,pulmonary lesion recovery,levels of inflammatory factors,and changes in immune cell levels were compared between the two groups.Results The treatment effectiveness rate in the obser-vation group was 95.16%,significantly higher than the 82.76%in the control group(P＜0.05).Furthermore,the sputum conversion rate,lesion absorption rate,and cavity closure rate in the observation group were significantly higher than those in the control group(P＜0.05).After treatment,the levels of TNF-α,CRP,and PCT in the observation group were significant-ly lower than in the control group(P＜0.05),while CD4+levels were higher and CD8+levels were lower in the observation group compared to the control group(P＜0.05).The incidence of adverse reactions showed no significant difference between the two groups(P＞0.05).Conclusion Isoniazid combined with moxifloxacin provides excellent therapeutic efficacy in the treatment of drug-resistant pulmonary tuberculosis,effectively reducing inflammatory response,with a high safety profile.
国家科技期刊平台
NSTL
万方数据
